We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Caution Advised When Using Vasopressin Septic Shock

By HospiMedica staff writers
Posted on 02 Jan 2008
Vasopressin should be used with great caution for the treatment of hypotension in septic shock, according to a new international study.

Researchers at the Washington University School of Medicine (St. More...
Louis, MI, USA) and other institutions in Iceland and Switzerland studied 32 pigs that were anesthetized, mechanically ventilated, and randomly assigned to one of four groups: Group S (sepsis) and group SV (sepsis and vasopressin) were exposed to fecal peritonitis; Group C and group V were non-septic controls. After 240 minutes, both septic groups were resuscitated with intravenous fluids; after 300 minutes, groups V and SV received intravenous vasopressin. Regional blood flow was measured in the hepatic and renal arteries, the portal vein, and the celiac trunk using ultrasonic transit time flowmetry. Microcirculatory blood flow was measured in the liver, kidney, and pancreas using laser Doppler flowmetry.

The researchers found that in septic shock, vasopressin decreased blood flow by 58% in the portal vein within an hour, and even after three hours the reduction stood at 45%. Blood flow in the liver, however, remained unchanged. The investigation also revealed that increased urine output did not necessarily reflect increased renal blood flow, and therefore may not be a useful indicator of the effects of a particular treatment. The study was published online on December 13, 2007, in the open access journal Critical Care.

"Vasopressin caused marked redistribution of splanchnic regional and microcirculatory blood flow, including a significant decrease in portal, pancreatic and renal blood flows, while hepatic artery flow remained virtually unchanged,” explained lead author Dr Vladimir Krejci, M.D., of the department of anesthesiology at Washington University medical school, and colleagues.

Vasopressin, a peptide hormone, is being developed as a new therapy for the hemodynamic support of septic shock and vasodilatory shock due to systemic inflammatory response syndrome, and has previously been shown in animal models to increase blood pressure in septic shock that fails to respond to catecholamines. However, the safety of vasopressin treatment in humans with septic shock is yet to be proven.


Related Links:
Washington University School of Medicine

Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Patient Preoperative Skin Preparation
BD ChloraPrep
New
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.